CEL-SCI is a biotechnology company engaged in research and development directed toward improving treatments for cancer and other diseases through utilization of the immune system – the body’s natural defense system. Multikine, the company’s lead investigational therapy, is being studied in a global Phase III clinical trial. Using its LEAPS technology program, CEL-SCI is additionally investigating an immunotherapy to potentially treat patients hospitalized with H1N1 and to serve as a vaccine for rheumatoid arthritis. For more information, visit the company’s Web site at www.cel-sci.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: